Galmed Pharmaceuticals (NASDAQ:GLMD)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Friday, November 10th. They presently have a $18.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 126.13% from the company’s previous close.
Several other equities analysts have also commented on GLMD. Maxim Group reiterated a “buy” rating and set a $14.00 price objective (up from $9.00) on shares of Galmed Pharmaceuticals in a research report on Monday, July 31st. Zacks Investment Research upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research report on Wednesday, August 2nd. Finally, Seaport Global Securities restated a “buy” rating and set a $19.00 price target on shares of Galmed Pharmaceuticals in a research report on Friday, October 6th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Galmed Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $18.30.
Galmed Pharmaceuticals (NASDAQ:GLMD) traded up $0.18 during trading hours on Friday, hitting $7.96. The company’s stock had a trading volume of 63,000 shares, compared to its average volume of 35,255. Galmed Pharmaceuticals has a 1 year low of $3.04 and a 1 year high of $9.59.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/galmed-pharmaceuticals-glmd-buy-rating-reiterated-at-hc-wainwright/1775318.html.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with our FREE daily email newsletter.